PerkinElmer Completes $5.25-Bn Acquisition of BioLegend
PerkinElmer has completed its $5.25-billion acquisition of BioLegend, a San Diego, California-based provider of life science antibodies and reagents.
BioLegend provides antibodies and reagents in areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing. BioLegend has more than 700 employees, based primarily in the US, and has estimated 2022 revenues of $380 million.
The acquisition was initially announced in July (July 2021).